Skip to content

Clinical observation of sequential topical Mometasone Furoate Cream versus Tapinarof in the treatment of atopic dermatitis in adults

Clinical observation of sequential topical Mometasone Furoate Cream versus Tapinarof in the treatment of atopic dermatitis in adults

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400093238
Enrollment
Unknown
Registered
2024-11-29
Start date
2024-12-01
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

Interventions

Observers:Apply mometasone cream topically once a night for 2 consecutive weeks, then switch to Benvemod ointment once in the morning and once in the evening, and continue using until 6 weeks
Control group A:Topical application of mometasone cream, once a night, for 2 consecutive weeks
Control Group B:Apply Benvemod ointment topically, once in the morning and once in the evening, continuously for 8 weeks

Sponsors

Xiangya Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Age range: 18-65 years old, male or female not limited; (2) Diagnosed according to the 2020 edition of the Chinese Guidelines for the Diagnosis and Treatment of Atopic Dermatitis according to the standard, the area of skin lesions accounts for 0-20% of the total body area, and the overall investigator rating (IGA) score is 2-3 points. (3) Willing to accept treat and sign informed consent form; (4) Women of childbearing age are willing to take effective contraceptive measures during the study period.

Exclusion criteria

Exclusion criteria: (1) Individuals who have had contact with the drug ingredients used in the research institute; (2) Within the past 2 weeks, the system has used glucocorticoids Immunosuppressants, biologics and other therapies; (3) There are serious cardiovascular, liver, kidney, respiratory system, and digestive problems systemic diseases, diabetes, and mental disorders; (4) Merge with other infected or inflammatory skin disease patients; (5) Pregnancy, planned pregnant, and lactating women.

Design outcomes

Primary

MeasureTime frame
Total efficiency;

Secondary

MeasureTime frame
IGA rating;Dermatology Quality of Life Index (DLQI);SCORAD rating;Recurrence rate;

Countries

CHINA

Contacts

Public ContactLI fangfang

Xiangya Hospital of Central South University

278645527@qq.com+86 137 5501 4943

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026